Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations [0.03%]
ROS1融合、扩增和突变与ROS1蛋白表达的相关性研究
Richard S P Huang,Amanda Gottberg-Williams,Panhia Vang et al.
Richard S P Huang et al.
Introduction: In this study, we sought to further characterize ROS1 protein expression in solid tumors with the complete spectrum of ROS1 genomic alterations. ...
Two-Year Follow-Up of a Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program [0.03%]
肺部癌症筛查项目中两项持续两年的随机控制吸烟戒断整合研究随访
Alain Tremblay,Niloofar Taghizadeh,Paul MacEachern et al.
Alain Tremblay et al.
Introduction: Smoking cessation activities incorporated into lung cancer screening programs have been broadly recommended, but studies to date have not exhibited increased quit rates associated with cessation programs in ...
A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review [0.03%]
一个新的EML4-ALK变异型3顺式G1202R/S1206Y双重突变顺序进化导致洛拉替尼耐药性：简报及文献回顾
Viola W Zhu,Misako Nagasaka,Russell Madison et al.
Viola W Zhu et al.
Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-A...
Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC [0.03%]
NSCLC中定义超进展疾病的不同方法的比较
Pedro Rocha,Didac Ramal,Enric Ripoll et al.
Pedro Rocha et al.
Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies...
A Novel LINC00478/ LINC01549 Intergenic Region -ALK Fusion Responded Well to Alectinib in a Patient With Lung Adenocarcinoma [0.03%]
LINC00478/LINC01549间隔区-ALK融合变异对Alectinib有良好反应的一位肺腺癌患者中的新型变异
Wei Peng,Si Li,Lijian Li et al.
Wei Peng et al.
Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC [0.03%]
广泛期小细胞肺癌患者的种族和其他医疗差异
Umit Tapan,Vanessa Fiorini Furtado,Muhammad Mustafa Qureshi et al.
Umit Tapan et al.
Introduction: Systemic treatment with chemotherapy is warranted for patients with extensive-stage SCLC (ES-SCLC). The objective of this study was to determine whether racial and other healthcare disparities exist in recei...
Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies [0.03%]
Taletrectinib（AB-106/DS-6051b）在ROS1阳性NSCLC中的疗效：美国和日本I期研究的更新综合分析
Sai-Hong Ignatius Ou,Yutaka Fujiwara,Alice T Shaw et al.
Sai-Hong Ignatius Ou et al.
Introduction: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. ...
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations [0.03%]
EGFR突变IV期NSCLC的日本肺癌协会指南
Kiichiro Ninomiya,Shunsuke Teraoka,Yoshitaka Zenke et al.
Kiichiro Ninomiya et al.
Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee...
Safe Delivery of Postoperative Radiotherapy for Thymic Carcinoma Located on the Outflow Graft of a Left Ventricular Assist Device [0.03%]
位于左心室辅助装置流出移植物上的胸腺癌术后放疗的安全递送
Genki Edward Sato,Yukinori Matsuo,Hideo Kanemitsu et al.
Genki Edward Sato et al.
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC [0.03%]
系列血浆游离循环肿瘤DNA测试可识别EGFR T790M阳性非小细胞肺癌中奥希替尼治疗结果早期预测的基因组变异
Bin-Chi Liao,Wei-Hsun Hsu,Jih-Hsiang Lee et al.
Bin-Chi Liao et al.
Introduction: Recent advances in the detection of genomic DNA from plasma samples allow us to follow tumor DNA shedding in plasma during systemic treatment. Osimertinib is the standard of care for patients with NSCLC with...